WestEnd Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.2K | Hold |
12
| – | – | ﹤0.01% | 149 |
|
|
2025
Q4 | $2.11K | Buy |
12
+8
| +200% | +$1.31K | ﹤0.01% | 156 |
|
|
2025
Q3 | $560 | Sell |
4
-2
| -33% | -$270 | ﹤0.01% | 298 |
|
|
2025
Q2 | $754 | Hold |
6
| – | – | ﹤0.01% | 237 |
|
|
2025
Q1 | $821 | Buy |
6
+4
| +200% | +$572 | ﹤0.01% | 227 |
|
|
2024
Q4 | $306 | Hold |
2
| – | – | ﹤0.01% | 221 |
|
|
2024
Q3 | $388 | Hold |
2
| – | – | ﹤0.01% | 205 |
|
|
2024
Q2 | $464 | Hold |
2
| – | – | ﹤0.01% | 167 |
|
|
2024
Q1 | $431 | Hold |
2
| – | – | ﹤0.01% | 161 |
|
|
2023
Q4 | $518 | Hold |
2
| – | – | ﹤0.01% | 156 |
|
|
2023
Q3 | $514 | Buy |
+2
| New | +$535 | ﹤0.01% | 151 |
|
|
2023
Q1 | – | Sell |
-2
| Closed | -$553 | – | 144 |
|
|
2022
Q4 | $554 | Hold |
2
| – | – | ﹤0.01% | 140 |
|
|
2022
Q3 | $1K | Hold |
2
| – | – | ﹤0.01% | 99 |
|
|
2022
Q2 | $407 | Buy |
+2
| New | +$409 | ﹤0.01% | 149 |
|
|
2022
Q1 | – | Sell |
-1
| Closed | -$217 | – | 231 |
|
|
2021
Q4 | $239 | Buy |
+1
| New | +$257 | ﹤0.01% | 239 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 203 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 183 |
|
|
2019
Q2 | – | Sell |
-109,859
| Closed | -$26M | – | 59 |
|
|
2019
Q1 | $26M | Buy |
109,859
+1,621
| +1% | +$510K | 2.44% | 24 |
|
|
2018
Q4 | $32.6M | Buy |
108,238
+3,493
| +3% | +$1.11M | 3.49% | 14 |
|
|
2018
Q3 | $37M | Sell |
104,745
-18,868
| -15% | -$6.5M | 3.54% | 18 |
|
|
2018
Q2 | $35.9M | Sell |
123,613
-9,174
| -7% | -$2.58M | 3.73% | 16 |
|
|
2018
Q1 | $36.4M | Sell |
132,787
-5,561
| -4% | -$1.73M | 3.43% | 19 |
|
|
2017
Q4 | $44.1M | Sell |
138,348
-40,710
| -23% | -$13.1M | 4.08% | 15 |
|
|
2017
Q3 | $56.1M | Sell |
179,058
-10,572
| -6% | -$3.13M | 4.92% | 4 |
|
|
2017
Q2 | $51.5M | Sell |
189,630
-15,124
| -7% | -$4M | 4.4% | 16 |
|
|
2017
Q1 | $56M | Buy |
204,754
+8,395
| +4% | +$2.37M | 4.68% | 11 |
|
|
2016
Q4 | $55.7M | Sell |
196,359
-29,310
| -13% | -$8.69M | 4.44% | 16 |
|
|
2016
Q3 | $70.6M | Sell |
225,669
-161,242
| -42% | -$47.8M | 5.07% | 2 |
|
|
2016
Q2 | $93.6M | Buy |
386,911
+17,212
| +5% | +$4.54M | 4.97% | 8 |
|
|
2016
Q1 | $96.2M | Buy |
369,699
+71,325
| +24% | +$18.8M | 4.67% | 18 |
|
|
2015
Q4 | $91.4M | Buy |
298,374
+9,658
| +3% | +$2.78M | 4.48% | 16 |
|
|
2015
Q3 | $84.3M | Buy |
288,716
+16,539
| +6% | +$5.46M | 4.26% | 19 |
|
|
2015
Q2 | $110M | Sell |
272,177
-6,345
| -2% | -$2.55M | 5.09% | 9 |
|
|
2015
Q1 | $118M | Sell |
278,522
-27,710
| -9% | -$10.9M | 5.29% | 3 |
|
|
2014
Q4 | $104M | Buy |
306,232
+17,170
| +6% | +$5.55M | 4.75% | 16 |
|
|
2014
Q3 | $95.6M | Sell |
289,062
-31,254
| -10% | -$10.3M | 4.83% | 19 |
|
|
2014
Q2 | $101M | Sell |
320,316
-386
| -0.1% | -$116K | 4.95% | 13 |
|
|
2014
Q1 | $98.1M | Buy |
320,702
+65,026
| +25% | +$20.6M | 4.79% | 17 |
|
|
2013
Q4 | $71.5M | Sell |
255,676
-89,564
| -26% | -$23.2M | 2.58% | 20 |
|
|
2013
Q3 | $83.1M | Sell |
345,240
-24,204
| -7% | -$5.42M | 2.72% | 21 |
|
|
2013
Q2 | $79.5M | Buy |
+369,444
| New | +$78.9M | 2.62% | 19 |
|
Other funds holding BIIB
VCM
VPM
WestEnd Advisors's BIIB Position: Q1 2026 in Review
WestEnd Advisors held its Biogen (BIIB) position steady in Q1 2026 at 12 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #149.
WestEnd Advisors first reported a position in BIIB in Q2 2013 and has held it in 39 quarters since. The position peaked at $118M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- WestEnd Advisors held 12 shares of Biogen worth $2.2K as of Q1 2026.
- WestEnd Advisors left its Biogen share count unchanged in Q1 2026.
- Biogen made up ﹤0.01% of WestEnd Advisors's portfolio in Q1 2026, its #149 holding.
- WestEnd Advisors first reported a position in Biogen in Q2 2013 and has held it in 39 quarters since.
- WestEnd Advisors's Biogen position peaked at $118M in Q1 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on WestEnd Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.